TREATMENT OF ARTERIAL HYPERTENSION AND DYSLIPIDEMIA IN REAL CLINICAL PRACTICE. THE SYNERGY STUDY. Part 2

Aim. To study the antihypertensive and hypolipidemic effect of therapy based on perindopril, including its combinations, and rosuvastatin in real clinical practice.

Material and methods. Analysis of the medical records of patients observed for hypertension (HT) and treated with perindopril, amlodipine and rosuvastatin in the multicenter nonintervention SYNERGY study was performed. Patients with established diagnosis of HT and registered elevated cholesterol blood level were included into the study. The drugs were prescribed by doctors in different doses. Data on the disease history, physical status, blood pressure (BP) measurements, and lipid blood levels were taken from the patient's medical records.

Results. 1736 patients (53% of women) with the mean age of 58.7 years were included into the analysis. 1322 patients (76.2%) previously received antihypertensive therapy, and 807 (46.5%) – lipid-lowering therapy. Reduction in systolic and diastolic BP, low density cholesterol blood level was found at the end of the study in all study groups s (p<0.05). This demonstrated an adequate antihypertensive and lipid-lowering effect of the applied treatment regimens. The average decrease in systolic BP was from 20.5 to 41.4 mm Hg, and this in diastolic BP – from 8.8 to 22.2 mm Hg. The maximum reduction in systolic BP was found in the group of perindopril 8 mg+amlodipine 10 mg+rosuvastatin 5 mg (41.4 mm Hg), and this in diastolic BP – in the group of perindopril 8 mg+rosuvastatin 10 mg. The mean decrease in low density cholesterol blood level was from 0.74 mmol/L in the group of perindopril 4 mg+amlodipine 10 mg+rosuvastatin 5 mg up to 1.75 mmol/l in the group of perindopril 8 mg+amlodipine 10 mg+rosuvastatin 20 mg

Conclusion: Therapy with perindopril, amlodipine and rosuvastatin resulted in significant reduction in BP and low-density cholesterol blood level in all the treatment groups. The study of the efficacy of combined therapy in patients with HT and dyslipidemia in real clinical practice makes it possible to evaluate the potential contribution of pharmacotherapy in reducing the risk of cardiovascular complications.

1. Stamler J., Wentworth D., Neaton J.D. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the multiple risk factor intervention trial. Am J Med. 1986;80(Suppl 2A):33-9

2. The seventh report of the joint national committee on prevention, detection, evaluation, and treatement of high blood pressure. JAMA 2003:289:2560-72

3. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014;23(1):3-16.

4. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62.

5. Diagnosis and treatment of hypertension. Russian recommendations. (Fourth revision). Sistemnie Gipertenzii. 2010;3:5-26. (In Russ.) [Диагностика и лечение артериальной гипертензии. Российские рекомендации. (четвертый пересмотр). Системные гипертензии. 2010;3:5-26]

6. Diagnosis and correction of lipid metabolism disorders for to prevent and treat atherosclerosis. Russian Guidelines. Available at: http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf. Checked by Jun 06, 2017. (In Russ.) [Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. Доступно на: http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf. Проверено 22.06.2017]

7. Lithell H., Hansson L., Skoog I., et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875-86

8. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28): 2159-219

9. Dusing R. Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag. 2010;6:321-5

10. Drapkina O.M., on behalf of SYNERGY researchers. Combination Therapy of High-Risk Patients in Real Clinical Practice. Results of SYNERGY Study. Part 1. Antihypertensive Branch. Rational Pharmacotherapy in Cardiology 2017;13(2):155-163. (In Russ). [Драпкина О.М., от имени исследователей СИНЕРГИЯ. Комбинированная терапия пациентов высокого риска в условиях реальной клинической практики. Результаты исследования СИНЕРГИЯ. Часть 1. Антигипертензивная ветвь. Рациональная фармакотерапия в кардиологии 2017;13(2):155-163]

11. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423

12. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427-31

13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97

14. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA). Lancet. 2003;361(9364):1149-58.

15. Winocour P. Drug therapy for prevention of cardiovascular disease - should surrogate measures be abandoned? Clin Med. 2005;5:282-7

16. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219

17. Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2012;33(13):1635-701

18. Mourad J.J. The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target. Vasc Health Risk Manag. 2008;4(6):1315-25

19. Hilleman D.E. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management. J Manag Care Pharm. 2014;20(1):93-100

20. Kostapanos M.S., Elisaf M.S., Mikhailidis D.P. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Curr Med Res Opin. 2012;28(9):1415-9.

21. Zyoud S.H., Al-Jabi S.W., Sweileh W.M., et al. Health-related quality of life associated with treatment adherence in patients with hypertension: a cross-sectional study. Int J Cardiol. 2013;168(3):2981-3.